Missteps in "tango" for epigenome targeting

Keith D. Robertson; Kapil N. Bhalla

doi:10.1182/blood-2009-07-231662

Missteps in "tango" for epigenome targeting

Keith D. Robertson, Kapil N. Bhalla

Dr. Mary and Ron Neal Cancer Center

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Abstract

In this issue of Blood, Fandy and colleagues describe the results of a trial in which leukemia patients were treated with 5-azacytidine (5-azaC) and the HDAC inhibitor, entinostat. ¹ Their results confirm the therapeutic efficacy of these agents but also demonstrate that we have much to learn about the mechanism of action of agents that target the epigenome.

Original language	English (US)
Pages (from-to)	2569-2570
Number of pages	2
Journal	Blood
Volume	114
Issue number	13
DOIs	https://doi.org/10.1182/blood-2009-07-231662
State	Published - 2009

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2009-07-231662

Cite this

@article{819469db877e4f60b6d64983df8dc1d1,

title = "Missteps in {"}tango{"} for epigenome targeting",

abstract = "In this issue of Blood, Fandy and colleagues describe the results of a trial in which leukemia patients were treated with 5-azacytidine (5-azaC) and the HDAC inhibitor, entinostat. 1 Their results confirm the therapeutic efficacy of these agents but also demonstrate that we have much to learn about the mechanism of action of agents that target the epigenome.",

author = "Robertson, {Keith D.} and Bhalla, {Kapil N.}",

year = "2009",

doi = "10.1182/blood-2009-07-231662",

language = "English (US)",

volume = "114",

pages = "2569--2570",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier B.V.",

number = "13",

}

TY - JOUR

T1 - Missteps in "tango" for epigenome targeting

AU - Robertson, Keith D.

AU - Bhalla, Kapil N.

PY - 2009

Y1 - 2009

N2 - In this issue of Blood, Fandy and colleagues describe the results of a trial in which leukemia patients were treated with 5-azacytidine (5-azaC) and the HDAC inhibitor, entinostat. 1 Their results confirm the therapeutic efficacy of these agents but also demonstrate that we have much to learn about the mechanism of action of agents that target the epigenome.

AB - In this issue of Blood, Fandy and colleagues describe the results of a trial in which leukemia patients were treated with 5-azacytidine (5-azaC) and the HDAC inhibitor, entinostat. 1 Their results confirm the therapeutic efficacy of these agents but also demonstrate that we have much to learn about the mechanism of action of agents that target the epigenome.

UR - http://www.scopus.com/inward/record.url?scp=70449480361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449480361&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-07-231662

DO - 10.1182/blood-2009-07-231662

M3 - Comment/debate

C2 - 19779044

AN - SCOPUS:70449480361

SN - 0006-4971

VL - 114

SP - 2569

EP - 2570

JO - Blood

JF - Blood

IS - 13

ER -

Missteps in "tango" for epigenome targeting

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this